Skip to content
Screener

EBITDA at other companies

Amgen logo
AmgenAMGN
$4.63B+15.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.42B+16.7%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$24.13M-31.9%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$15.3M-26.4%
Savara logo
SavaraSVRA
-$40.94M-30.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.51M-26.0%

Other financials

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$394.54M-54.7%
Enterprise value$316.1M-61.6%
P/S124.9×-195×

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%
Debt / equity0.0×
Current ratio28×-10.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

$42.4Mebit+
$50.0KDepreciation Depletion & Amortization
=-$42.32M

The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-343417

FAQ

What is Upstream Bio, Inc.'s EBITDA?
Upstream Bio, Inc. (UPB) reported EBITDA of -$42.32M in Q2 2026.
How has Upstream Bio, Inc.'s EBITDA changed year-over-year?
Upstream Bio, Inc.'s EBITDA increased by 4.5% year-over-year, from -$44.31M to -$42.32M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Upstream Bio, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude